Eaton D, Lynn A, Surprenant J, Deschenes E, Guerra M, Rivero R
Biomed Hub. 2025; 10(1):23-32.
PMID: 39845408
PMC: 11753793.
DOI: 10.1159/000543138.
Yadav S, Dhuri K, Gamiotea-Turro D, Cormier M, Patel V, Yadawa A
Mol Ther Nucleic Acids. 2024; 35(4):102355.
PMID: 39507400
PMC: 11539414.
DOI: 10.1016/j.omtn.2024.102355.
Gupta P, Sharma A, Mittal V
Recent Adv Drug Deliv Formul. 2024; 18(4):276-293.
PMID: 39356099
DOI: 10.2174/0126673878324536240805060143.
Shin K, Suh H, Suberi A, Whang C, Ene M, Grundler J
Biomaterials. 2024; 311:122692.
PMID: 38986360
PMC: 11298310.
DOI: 10.1016/j.biomaterials.2024.122692.
Tang Q, Khvorova A
Nat Rev Drug Discov. 2024; 23(5):341-364.
PMID: 38570694
PMC: 11144061.
DOI: 10.1038/s41573-024-00912-9.
Influencing Endothelial Cells' Roles in Inflammation and Wound Healing Through Nucleic Acid Delivery.
Lallo V, Bracaglia L
Tissue Eng Part A. 2023; 30(7-8):272-286.
PMID: 38149606
PMC: 11040193.
DOI: 10.1089/ten.TEA.2023.0296.
Nano-delivery systems as a promising therapeutic potential for epilepsy: Current status and future perspectives.
Movahedpour A, Taghvaeefar R, Asadi-Pooya A, Karami Y, Tavasolian R, Khatami S
CNS Neurosci Ther. 2023; 29(11):3150-3159.
PMID: 37452477
PMC: 10580365.
DOI: 10.1111/cns.14355.
Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases.
Kurakula H, Vaishnavi S, Sharif M, Ellipilli S
ACS Omega. 2023; 8(23):20234-20250.
PMID: 37323391
PMC: 10268023.
DOI: 10.1021/acsomega.3c01703.
Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment.
Chang J, Yu B, Saltzman W, Girardi M
JID Innov. 2023; 3(4):100197.
PMID: 37205301
PMC: 10186617.
DOI: 10.1016/j.xjidi.2023.100197.
delivery of miRNA induces epigenetic alterations and corrects pulmonary pathology in congenital diaphragmatic hernia.
Ullrich S, Yung N, Bauer-Pisani T, Maassel N, Guerra M, Freedman-Weiss M
Mol Ther Nucleic Acids. 2023; 32:594-602.
PMID: 37200861
PMC: 10185702.
DOI: 10.1016/j.omtn.2023.04.018.
Biopolymer Nanoparticles for Nose-to-Brain Drug Delivery: A New Promising Approach for the Treatment of Neurological Diseases.
Montegiove N, Calzoni E, Emiliani C, Cesaretti A
J Funct Biomater. 2022; 13(3).
PMID: 36135560
PMC: 9504125.
DOI: 10.3390/jfb13030125.
Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles.
Khoza L, Kumar P, Dube A, Demana P, Choonara Y
Int J Pharm. 2022; 622:121893.
PMID: 35680110
PMC: 9169426.
DOI: 10.1016/j.ijpharm.2022.121893.
Nanodelivery of nucleic acids.
Mendes B, Conniot J, Avital A, Yao D, Jiang X, Zhou X
Nat Rev Methods Primers. 2022; 2.
PMID: 35480987
PMC: 9038125.
DOI: 10.1038/s43586-022-00104-y.
Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.
Zhang Y, Almazi J, Ong H, Johansen M, Ledger S, Traini D
Int J Mol Sci. 2022; 23(5).
PMID: 35269550
PMC: 8909959.
DOI: 10.3390/ijms23052408.
Fused deposition modeling three-dimensional printing of flexible polyurethane intravaginal rings with controlled tunable release profiles for multiple active drugs.
Chen Y, Traore Y, Walker L, Yang S, Ho E
Drug Deliv Transl Res. 2022; 12(4):906-924.
PMID: 35211869
PMC: 8870081.
DOI: 10.1007/s13346-022-01133-6.
Long-acting and extended-release implant and nanoformulations with a synergistic antiretroviral two-drug combination controls HIV-1 infection in a humanized mouse model.
Beloor J, Kudalkar S, Buzzelli G, Yang F, Mandl H, Rajashekar J
Bioeng Transl Med. 2022; 7(1):e10237.
PMID: 35079625
PMC: 8780078.
DOI: 10.1002/btm2.10237.
Multicellular Ovarian Cancer Model for Evaluation of Nanovector Delivery in Ascites and Metastatic Environments.
Winter S, Miller H, Steinbach-Rankins J
Pharmaceutics. 2021; 13(11).
PMID: 34834307
PMC: 8625169.
DOI: 10.3390/pharmaceutics13111891.
E7-Targeted Nanotherapeutics for Key HPV Afflicted Cervical Lesions by Employing CRISPR/Cas9 and Poly (Beta-Amino Ester).
Xiong J, Tan S, Yu L, Shen H, Qu S, Zhang C
Int J Nanomedicine. 2021; 16:7609-7622.
PMID: 34819726
PMC: 8606985.
DOI: 10.2147/IJN.S335277.
Thymopentin alleviates premature ovarian failure in mice by activating YY2/Lin28A and inhibiting the expression of let-7 family microRNAs.
Liu T, Jing F, Huang P, Geng Z, Xu J, Li J
Cell Prolif. 2021; 54(8):e13089.
PMID: 34180104
PMC: 8349654.
DOI: 10.1111/cpr.13089.
Extension in the approaches to treat cancer through siRNA system: a beacon of hope in cancer therapy.
Rautela I, Sharma A, Dheer P, Thapliyal P, Sahni S, Sinha V
Drug Deliv Transl Res. 2021; 12(5):1002-1016.
PMID: 33970462
DOI: 10.1007/s13346-021-00995-6.